Quarterly ResultMay 7, 2026, 04:36 PM
ImageneBio Q1 Net Loss Widens to $10.6M; Cash Burn Doubles
AI Summary
ImageneBio, Inc. reported a net loss of $10.6 million for the first quarter of 2026, a significant increase from $6.1 million in the prior year. The company's cash used in operating activities more than doubled to $14.8 million. This follows the July 2025 merger of Ikena Oncology and Legacy Inmagene, which was accounted for as a reverse recapitalization, and a concurrent $75.0 million PIPE financing. The company also disclosed a material weakness in internal control over financial reporting and expects to incur significant losses, requiring substantial additional funding.
Key Highlights
- Net loss for Q1 2026 widened to $10.6 million, up from $6.1 million in Q1 2025.
- Cash used in operating activities more than doubled to $14.8 million in Q1 2026.
- Research and development expenses increased to $6.0 million in Q1 2026 from $4.0 million in Q1 2025.
- General and administrative expenses rose to $6.1 million in Q1 2026 from $2.8 million in Q1 2025.
- Interest income was $1.1 million in Q1 2026, compared to an expense of $0.1 million in Q1 2025.
- Cash and cash equivalents were $76.0 million as of March 31, 2026, down from $94.5 million at Dec 31, 2025.
- Company identified a material weakness in internal control over financial reporting.
- Anticipates existing funds plus $30.0 million from April 2026 private placement to last 12+ months.